Sun Pharma Advanced Research Company Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/01/2026 ,inter alia, to consider and approve the proposal ....
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma Advanced Research Company (SPARC) has informed BSE that its board will meet on January 14, 2026 to consider two key items. First, a proposal to raise funds through a preferential issue of securities, including convertible warrants, to an identified member of the promoter group, under SEBI ICDR regulations. Second, approval of a new Employee Stock Option Scheme (ESOS) under SEBI's SBEB regulations. The trading window for dealing in SPARC shares has been closed since January 1, 2026. The proposal still requires shareholder and exchange approvals before it can proceed.
A preferential issue to the promoter group signals potential further capital infusion from the existing promoters, which could be positive for confidence but may also lead to promoter shareholding increase. Combined with a new ESOS, this indicates upcoming equity dilution for existing shareholders.